Dexmedetomidine Hydrochloride

CHEMBL2106195 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

236.7 g/mol

LogP

—

Phase

4

The hydrochloride salt form of dexmedetomidine used intravenously for ICU sedation and monitored anesthesia care sedation. It produces cooperative sedation where patients remain arousable, making it valuable for neurological assessments.

Masse moléculaire

236,7400 g/mol

TPSA

28,70 Å²

Aires thérapeutiques

Pain Management Non-Small Cell Lung Cancer Asthma Chronic Obstructive Pulmonary Disease Parkinson's Disease Schizophrenia Generalized Anxiety Disorder Insomnia Deep Vein Thrombosis / Pulmonary Embolism Obesity Hypertension Breast Cancer Chronic Pain Heart Failure Atrial Fibrillation

Mécanisme d'action

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl

InChI

InChI=1S/C13H16N2.ClH/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13;/h4-8,11H,1-3H3,(H,14,15);1H/t11-;/m0./s1

Molecular Formula

C13H17ClN2

HBD / HBA

2 / 1

Liaisons Rotatives

2

Atomes Lourds

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

The hydrochloride salt form of dexmedetomidine used intravenously for ICU sedation and monitored anesthesia care sedation. It produces cooperative sedation where patients remain arousable, making it valuable for neurological assessments.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Dexmedetomidine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2106195. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6918081. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Dexmedetomidine Hydrochloride sur PillFYI

Structure

Données Clés

Formule: C13H17ClN2
Synonymes: 9

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.